A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis
NCT ID: NCT05970432
Last Updated: 2023-08-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
160 participants
INTERVENTIONAL
2023-06-19
2024-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis
NCT06552520
A Study of TQH2722 Injection to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Immunogenicity in Healthy Adult Subjects
NCT05409326
A Phase 2 Study to Evaluate the Efficacy, Safety of SIM0278 in Subjects With Moderate to Severe Atopic Dermatitis
NCT07175233
Evaluate the Efficacy and Safety of XKH001 Injection in Patients With Moderate-to-Severe Atopic Dermatitis
NCT07054736
A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis
NCT07211542
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TQH2722 injection 300mg-150mg
Participants received subcutaneous injection of 300 mg TQH2722 injection + 600 mg placebo on day 1, followed by subcutaneous injection of 150 mg TQH2722 injection + 300 mg placebo on days 15, 29, 43, 57, 71, 85, 99.
TQH2722 injection 300mg-150mg
TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.
TQH2722 injection 600mg-300mg
Participants received subcutaneous injection of 600 mg TQH2722 injection + 300 mg placebo on day 1, followed by subcutaneous injection of 300 mg TQH2722 injection + 150 mg placebo on days 15, 29, 43, 57, 71, 85, 99.
TQH2722 injection 600mg-300mg
TQH2722 injection is a fully human monoclonal antibody that thereby interfering with the signal cascade.
TQH2722 injection 900mg-450mg
Participants received subcutaneous injection of 900 mg TQH2722 injection on day 1, followed by subcutaneous injection of 450 mg TQH2722 injection on days 15, 29, 43, 57, 71, 85, 99.
TQH2722 injection 900mg-450mg
TQH2722 injection is a fully human monoclonal antibody that thereby interfering with the signal cascade.
TQH2722 injection matching Placebo
Subjects received 900mg placebo injection subcutaneously on day 1, followed by 450mg placebo injection on days 15, 29, 43, 57, 71, 85, 99.
TQH2722 injection matching Placebo
Placebo without active substance.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TQH2722 injection 300mg-150mg
TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.
TQH2722 injection 600mg-300mg
TQH2722 injection is a fully human monoclonal antibody that thereby interfering with the signal cascade.
TQH2722 injection 900mg-450mg
TQH2722 injection is a fully human monoclonal antibody that thereby interfering with the signal cascade.
TQH2722 injection matching Placebo
Placebo without active substance.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Meets 2014 American Academy of Dermatology (AAD) criteria with diagnosis of atopic dermatitis (AD); In addition, history of AD prior to screening ≥ 6 months; Eczema was previously diagnosed but met the 2014 AAD criteria and can still be enrolled.
* Patients with moderate to severe AD at screening and baseline visit (shall meet all 3 criteria as follows):
1. total area of AD lesions≥ 10% BSA;
2. IGA ≥3 points;
3. EASI ≥ 16 points;
* Baseline peak pruritus NRS ≥4 (The average peak pruritus intensity score in baseline peak pruritus NRS will be calculated based on the average of the peak pruritus intensity NRS score (daily score range 0-10) for each day during the 7 days prior to randomization. A minimum of 4 days out of 7 days of scoring is required to calculate the baseline average score. If the patient's reporting days are less than 4 days in the 7 days prior to the planned randomization date, randomization should be postponed until the requirements are met, but not beyond the maximum period of 14 days for screening);
* 6 months prior to the screening period, insufficient response to stable (≥1 month) topical corticosteroids (TCS) or calcineurin inhibitors (TCI) (insufficient response defined as at least 28 days even if the daily regimen of moderate-high potency TCS (± topical TCI, if applicable) is at least 28 days, or to the maximum recommended course of treatment (eg, ultra-potent TCS - 14 days) in the product prescribing information (whichever is shorter), Failure to achieve or maintain disease remission or low disease activity (equivalent to IGA 0 \[=none\]-2 \[=mild\]). or patients who have received a record of systemic treatment (adequate dose, adequate course) of AD in the past 6 months are also considered to have insufficient response to topical drug therapy, and may be selected for trial after appropriate drug elution and approval by the sponsor);
* Before the first dose, subjects must have continuously used the emollient twice a day for at least 1 week and maintained throughout the trial (Note: the emollient is provided by the sponsor);
* Be able to read and understand, and be willing to sign informed consent forms;
* Willingness and compliance with research visits and related procedures;
* Female participants of childbearing age should agree that contraception (e.g., intrauterine devices, pills, or condoms) must be used during the study period and for 6 months after the end of the study; Negative serum pregnancy test within 7 days prior to first dose and must be a non-lactating subject; Male subjects should agree that contraception must be used during the study period and for 6 months after the end of the study period.
Exclusion Criteria
1. Have used any of the following treatments within 4 weeks or the investigator believes that the following treatments may be required: immunosuppressants/immunomodulatory drugs (eg, systemic glucocorticosteroids, cyclosporine, mycophenolate mofetil, interferon γ (IFN-γ), azathioprine, and methotrexate); AD phototherapy;
2. Oral Janus Kinase (JAK) inhibitors (including but not limited to upadacitinib) used within 2 weeks;
3. Received systemic traditional Chinese medicine (TCM) treatment within 4 weeks; or within 1 week, topical TCM;
4. Treated with leukotriene inhibitors within 4 weeks;
5. Treated with topical preparations of TCS or TCI or phosphodiesterase 4 (PDE⁃4) inhibitors within 2 weeks;
6. Treatment with the following biologics: any cell depleting agent, including but not limited to rituximab: within 6 months or until the lymphocyte count returns to normal, whichever is longer; Other biologics: 5 half-lives (if half-life known) or 12 weeks (whichever is longer); Within 4 weeks, receive regular phototherapy (including but not limited to narrow-spectrum UVB, psoralen longwave ultraviolet therapy, etc.) or use artificial sunbathing sheds/rooms;
7. Within 12 weeks, receive live (attenuated) vaccine;
8. Chronic active or acute infection requiring systemic treatment with antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks, or superficial skin infection within 1 week prior to baseline visit. After the infection resolves, screening can be renewed;
9. Antihistamines (including oral, nasal, and topical preparations) within 1 week;
* Abnormal physical examination results during screening or any of the following laboratory tests:
1. Hemoglobin\< 110 g/L
2. White blood cell (WBC) \< 3.5 x 10\^9/L
3. Platelet count \< 125 x 10\^9/L
4. Neutrophils\< 1.75 x 10\^9/L • Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \>1.5 x upper limit of normal (ULN)
5. Total bilirubin \> 1.5 x ULN (except indirect bilirubin elevation secondary to Gilbert syndrome)
6. Creatinine \> 1.5 x ULN
7. Creatine phosphokinase (CPK) \> 2 x ULN
* There are cutaneous comorbidities that may interfere with the study assessment, including but not limited to scabies, seborrheic dermatitis, cutaneous T-cell lymphoma, psoriasis, etc
* Concomitant other serious medical conditions that, at the discretion of the investigator, may adversely affect participants' participation in this study, including, but not limited to: short life expectancy, history of uncontrolled diabetes (HbA1c ≥ 9%), cardiovascular disease (eg, grade III or IV heart failure, graded according to the New York Heart Association), severe kidney disease (eg, patients on dialysis), hepatobiliary disease (e.g., Child-Pugh class B or C), neurological disease (e.g., demyelinating disease), Patients with important active autoimmune diseases (eg, lupus, inflammatory bowel disease, rheumatoid arthritis, etc.), as well as other severe endocrine, gastrointestinal, metabolic, pulmonary, or lymphatic diseases.
* Have a history of known or suspected immunosuppression, including invasive opportunistic infections (e.g., histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, and aspergillosis), even if the infection has resolved; or unusual frequent, recurrent, or long-term infections (at the investigator's discretion);
* Subjects with any type of active malignancy or a history of malignancy (except cervical cancer or non-metastatic cutaneous squamous cell carcinoma, basal cell carcinoma and papillary thyroid carcinoma) that has been cured for more than 5 years prior to the screening period;
* Computed Tomography (CT) of the chest shows active or occult tuberculosis or a history of contact with an open tuberculosis (TB) subject within the past 6 months. If the laboratory T cell spot test for tuberculosis infection test (or other tuberculosis diagnostic test) is positive, its activity is judged in combination with the medical history, clinical manifestations, etc., and the investigator determines whether it can be enrolled;
* Active hepatitis during the screening period, or positive for hepatitis B surface antigen (HBsAg), or positive for hepatitis B core antibody (HBcAb);
* History of human immunodeficiency virus (HIV) infection, or positive HIV serological results at screening, and positive antibodies to treponema pallidum during screening
* Positive for treponemal pallidum antibodies during screening
* Parasitic infection related to any of the following is excluded:
1. Routine inspection of worm eggs during the screening period;
2. History of parasitic infection within 6 months prior to the screening period, except for cured trichomoniasis;
* Have participated in clinical trials of other drugs or medical devices within 12 weeks prior to screening
* During the period of participation in this study, participants had planned surgical procedures
* Pregnant or lactating women
* People who are alcoholic, drug addicts, and known drug dependents
* In the judgment of the investigator or sponsoring medical auditor, it is believed that there are any medical or psychiatric symptoms that put the subject at risk, interfere with participation in the study, or interfere with the interpretation of the results of the study.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital of Wannan Medical College
Wuhu, Anhui, China
Dermatology Hospital, Southern Medical University
Guangzhou, Guangdong, China
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Shenzhen People's Hospital
Shenzhen, Guangdong, China
Affiliated Hospital of Guilin Medical University
Guilin, Guangxi, China
Affiliated Hospital of Hebei Engineering University
Handan, Hebei, China
The Forth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
The second affiliated hospital of harbin medical university
Harbin, Heilongjiang, China
Puyang District Hospital of Anyang City
Anyang, Henan, China
The First People's Hospital of Nanyang
Nanyang, Henan, China
People's Hospital of Henan province
Zhengzhou, Henan, China
Shiyan Renmin Hospital
Shiyan, Hubei, China
Renmin Hospital of Wuhan University
Wuhan, Hubei, China
The third xiangya hospital of central south university
Changsha, Hunan, China
Qian-jin Lu
Nanjing, Jiangsu, China
Affiliated Hospital of Jiujiang University
Jiujiang, Jiangxi, China
The Second Hospital of Jilin University
Changchun, Jilin, China
Panjin Liaoyou Gem Flower Hospital
Panjin, Liaoning, China
The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China
Air Force Medical University
Xi'an, Shaanxi, China
The Second Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China
Shengli Oil Field Central Hospital
Dongying, Shandong, China
Shandong First Medical University Affiliated Dermatology Hospital
Jinan, Shandong, China
Qilu Hospital of Shandong University
Jinan, Shandong, China
The Affiliated Hospital Of Qingdao University
Qingdao, Shandong, China
Huashan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, China
Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
Tianjin, Tianjin Municipality, China
Xinjiang Uygur Autonomous Region People's Hospital
Ürümqi, Xinjiang Uygur Autonomous Region, China
The First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
The First People's Hospital of Wenling
Wenling, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TQH2722-II-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.